- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, January 15, 2021
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by Becker’s Hospital Review spotlighted a commentary published in the January 2021 Health Information Technology special issue of The American Journal of Managed Care® (AJMC®). The commentary, “Addressing Evolving Patient Concerns Around Telehealth in the COVID-19 Era,” highlighted that with the rapid shift to telehealth during the coronavirus disease 2019 pandemic, clinicians, health care organizations, and policy makers must consider and address patients’ evolving needs, concerns, and expectations.
An article published on AJMC.com, the website of AJMC®, was spotlighted by Healthline. The article, “Abbott's Freestyle Libre CGM Gains Medicare Coverage,” reported on a factory-calibrated continuous glucose monitoring system touted as less expensive, with a spokeswoman saying it will not require bundling with a meter, which is required for a competitor.
In a press release issued by KMK Consulting and published on EIN Presswire, a report published in a supplement to AJMC®, “Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective,” was referenced. The report, titled, “Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management,” noted that treatment for multiple sclerosis should be individualized and shared decision-making between patients and health care providers must be preserved.
Unique Psychological Burden of Fear of Progression Seen in MG
August 6th 2025Fear of progression is common among patients living with chronic diseases, but the degree to which it interferes with patient outcomes, including treatment adherence, deserves further investigation, study authors note.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
